Overexpression of both IPOα and IPOβ has been reported in non-Hodgkin lymphoma [77], myeloma [78], and leukemia [79] as well as many solid tumors, and is frequently correlated with poor prognosis and a more aggressive tumor phenotype [1, 80]. Here, SOD1 is linked to leukemia.